- Oops!Something went wrong.Please try again later.
NEW HAVEN, Conn., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will present a Company overview, as well as host investor meetings, at the Stifel 2019 Healthcare Conference:
Date: November 19, 2019
Presentation Time: 9:10 a.m. ET
Place: Lotte New York Palace Hotel, New York
A live webcast of the presentation can be accessed by visiting ‘News & Events’ in the Investor & News section on the Company's website at www.trevitherapeutics.com. An archived replay of the webcast will be available for 90 days on the Company's website following the conference.
The corporate presentation that the Company intends to present with and at the time of the live webcast will be posted to its website under ‘Investor & News’.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.
About Nalbuphine ER
Nalbuphine ER is an oral extended release formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine’s mechanism of action also mitigates the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. Nalbuphine is currently the only opioid approved for marketing that is not classified as a controlled substance in the United States and most of Europe.
212-537-5177 ext. 7